GLP-1 Market
LLY $1437.29 ▲ +0.3% NVO $41.09 ▲ +1.0% PFE $29.45 ▲ +0.3% VKTX $28.44 ▼ -0.8% KLRA $14.38 ▲ +1.0% GPCR $20.95 ▼ -3.6% RHHBY $60.60 ▼ -0.8%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LCI699

Company
Novartis
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 12, 2026

Find a Clinical Trial Near Me

See recruiting studies for LCI699 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03708900

    Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

    Not yet reported RECORDATI GROUP 12 participants Est. completion 2027-07-21 15 sites Stand-alone
    Other conditions: Cushing Syndrome
    View official trial listing →
  • Recruiting NCT NCT06430528

    A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

    University of Michigan 12 participants Est. completion 2028-01 1 site
    Other conditions: Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
    View official trial listing →
  • Recruiting NCT NCT07104812

    Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

    Not yet reported Mayo Clinic 15 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
    View official trial listing →
  • Recruiting NCT NCT07247058

    Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

    Not yet reported Johns Hopkins University 10 participants Est. completion 2029-03 1 site Stand-alone
    Other conditions: Mild Autonomous Cortisol Secretion (MACS)
    View official trial listing →
  • Recruiting NCT NCT07247162

    Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

    Not yet reported RECORDATI GROUP 63 participants Est. completion 2028-07 3 sites Stand-alone
    Other conditions: Hypertension, Hypercortisolemia, Cushing Syndrome
    View official trial listing →
  • Recruiting NCT NCT07268222

    Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

    Not yet reported Laikο General Hospital, Athens 150 participants Est. completion 2027-11-25 1 site
    Other conditions: Mild Autonomous Cortisol Secretion (MACS)
    View official trial listing →
  • Completed NCT NCT00732771

    Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

    Not yet reported Novartis 12 participants 1 site Stand-alone
    Other conditions: Primary Hyperaldosteronism
    View official trial listing →
  • Completed NCT NCT00758524

    A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

    Not yet reported Novartis Pharmaceuticals 628 participants Est. completion 2009-07-02 1 site Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT00817414

    A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

    Not yet reported Novartis 63 participants Est. completion 2009-08-12 11 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00817635

    A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

    Not yet reported Novartis 155 participants Est. completion 2009-10-13 38 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT01331239

    Safety and Efficacy of LCI699 in Cushing's Disease Patients

    Not yet reported Novartis Pharmaceuticals 31 participants Est. completion 2019-10-22 10 sites Stand-alone
    Other conditions: Cushings Disease, Cushing Disease
    View official trial listing →
  • Completed NCT NCT02180217

    Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 137 participants Est. completion 2019-12-04 60 sites Stand-alone
    Other conditions: Cushings Disease
    View official trial listing →
  • Completed NCT NCT02372084

    A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

    Not yet reported Novartis Pharmaceuticals 33 participants Est. completion 2016-05-19 3 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT02399202

    A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

    Not yet reported Novartis Pharmaceuticals 15 participants Est. completion 2016-03-21 2 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT02468193

    Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2018-10-29 4 sites Stand-alone
    Other conditions: Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma, AIMAH, PPNAD
    View official trial listing →
  • Completed NCT NCT02697734

    Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 73 participants Est. completion 2020-12-31 36 sites Stand-alone
    Other conditions: Cushing's Disease
    View official trial listing →
  • Completed NCT NCT03606408

    Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

    Not yet reported RECORDATI GROUP 127 participants Est. completion 2023-11-16 56 sites
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05382156

    Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

    RECORDATI GROUP 206 participants Est. completion 2027-08 43 sites
    Other conditions: Endogenous Cushing's Syndrome
    View official trial listing →
  • Completed NCT NCT05633953

    Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

    RECORDATI GROUP 103 participants Est. completion 2023-10-30 1 site
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Status unknown NCT NCT06131580

    Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome

    Not yet reported Centre hospitalier de l'Université de Montréal (CHUM) 7 participants Est. completion 2025-11-24 3 sites
    Other conditions: Endogenous Cushing Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT06701838

    Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

    Imperial College London 15 participants Est. completion 2026-07-05
    Other conditions: Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
    View official trial listing →
  • Enrolling by invitation NCT NCT07603466

    Combination Osilodrostat and Cabergoline in Cushing's Disease

    Not yet reported University of Basrah 50 participants Est. completion 2028-08 5 sites
    Other conditions: Cushing Disease Due to Increased ACTH Secretion
    View official trial listing →
  • Not yet recruiting NCT NCT07922148

    Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

    Not yet reported Beckey Trinh 44 participants Est. completion 2029-10 1 site Stand-alone
    Other conditions: Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: LCI699, Osilodrostat (Isturisa), Osilodrostat, Isturisa

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.